Maximus (NYSE:MMS) Updates FY 2026 Earnings Guidance

Maximus (NYSE:MMS) updated its FY 2026 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 8.050-8.350 for the period, compared to the consensus estimate of 8.180. The company issued revenue guidance of $5.2 billion-$5.4 billion, compared to the consensus revenue estimate of $5.5 billion.

Maximus Stock Down 16.6%

NYSE:MMS traded down $15.56 during midday trading on Thursday, reaching $78.13. 2,199,235 shares of the stock traded hands, compared to its average volume of 607,090. The stock has a market capitalization of $4.26 billion, a PE ratio of 14.05 and a beta of 0.57. Maximus has a 12-month low of $63.77 and a 12-month high of $100.00. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.64 and a current ratio of 1.64. The business has a 50-day moving average of $90.45 and a two-hundred day moving average of $86.41.

Maximus (NYSE:MMS) last issued its quarterly earnings results on Thursday, February 5th. The health services provider reported $1.85 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.84 by $0.01. The business had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.37 billion. Maximus had a return on equity of 25.23% and a net margin of 5.87%.The business’s quarterly revenue was down 4.1% on a year-over-year basis. During the same period in the prior year, the firm posted $1.61 earnings per share. Maximus has set its FY 2026 guidance at 8.050-8.350 EPS. On average, equities analysts forecast that Maximus will post 6.15 earnings per share for the current fiscal year.

Maximus Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 2nd. Stockholders of record on Friday, February 13th will be issued a dividend of $0.33 per share. This represents a $1.32 annualized dividend and a dividend yield of 1.7%. This is an increase from Maximus’s previous quarterly dividend of $0.30. The ex-dividend date is Friday, February 13th. Maximus’s dividend payout ratio is currently 21.58%.

Wall Street Analyst Weigh In

A number of analysts recently commented on MMS shares. Zacks Research upgraded shares of Maximus from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, December 30th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Maximus in a research note on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating and one has assigned a Buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Strong Buy”.

Insider Activity at Maximus

In other news, insider Michelle F. Link sold 4,039 shares of the stock in a transaction on Wednesday, December 3rd. The shares were sold at an average price of $86.84, for a total value of $350,746.76. Following the sale, the insider owned 19,542 shares in the company, valued at $1,697,027.28. This represents a 17.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.80% of the stock is owned by company insiders.

Key Stories Impacting Maximus

Here are the key news stories impacting Maximus this week:

• Positive Sentiment: Q1 EPS beat consensus: Maximus reported $1.85 EPS vs. $1.84 consensus and up from $1.61 a year ago; profitability metrics (ROE ~25%, net margin ~5.9%) remain solid — suggests underlying earnings strength. Business Wire: Q1 Results
• Neutral Sentiment: FY2026 EPS guidance set to $8.05–$8.35 (consensus ≈ $8.18) — range overlaps consensus, so guidance on earnings is roughly in line though not clearly better. Earnings Call Transcript
• Neutral Sentiment: Analyst writeups (Zacks) provide context on valuation and metric comparisons — useful for investors deciding if the near-term revenue softness is a buying opportunity. Zacks: Should Value Investors Buy?
• Negative Sentiment: Revenue miss and y/y decline: Q1 revenue was $1.35B vs. ~$1.37B expected and down ~4.1% year-over-year — top-line softness weighs on growth narrative and multiple. MarketBeat: Q1 Results and Materials
• Negative Sentiment: Revenue guidance trimmed below street: company set FY revenue guidance at ~$5.2B–$5.4B versus consensus near $5.5B — implies continued near-term top-line pressure and prompted investor re-pricing. Business Wire: Guidance
• Negative Sentiment: Stock reaction and volume: shares are down on the news and traded at elevated volume versus average — indicates broad investor selling and re‑assessment of growth prospects. MarketBeat: MMS Quote & Volume

Hedge Funds Weigh In On Maximus

Several institutional investors and hedge funds have recently modified their holdings of MMS. Boston Partners grew its holdings in Maximus by 47.0% during the third quarter. Boston Partners now owns 966,139 shares of the health services provider’s stock worth $88,236,000 after acquiring an additional 308,892 shares during the period. Bank of America Corp DE grew its stake in shares of Maximus by 24.6% during the 3rd quarter. Bank of America Corp DE now owns 453,616 shares of the health services provider’s stock worth $41,447,000 after purchasing an additional 89,693 shares during the period. Qube Research & Technologies Ltd increased its holdings in shares of Maximus by 115.8% during the 2nd quarter. Qube Research & Technologies Ltd now owns 379,342 shares of the health services provider’s stock valued at $26,630,000 after purchasing an additional 203,521 shares in the last quarter. Wellington Management Group LLP increased its holdings in shares of Maximus by 6.3% during the 3rd quarter. Wellington Management Group LLP now owns 374,108 shares of the health services provider’s stock valued at $34,182,000 after purchasing an additional 22,111 shares in the last quarter. Finally, UBS Group AG lifted its stake in shares of Maximus by 4.6% in the 3rd quarter. UBS Group AG now owns 345,259 shares of the health services provider’s stock valued at $31,546,000 after purchasing an additional 15,044 shares during the period. Institutional investors and hedge funds own 97.21% of the company’s stock.

Maximus Company Profile

Maximus, Inc (NYSE: MMS) is a global provider of government services focused on delivering health and human services programs. The company partners with federal, state, and local agencies to administer and manage programs that support individuals and families across various stages of life. Key service areas include eligibility determination and enrollment services for Medicaid, Medicare, Children’s Health Insurance Program (CHIP) and other public assistance programs, as well as call center operations, case management and program integrity solutions.